A unified approach to the applicability domain problem of QSAR models
© Dragos et al; licensee BioMed Central Ltd. 2010
Published: 04 May 2010
The present work proposes a unified conceptual framework to describe and quantify the important issue of the Applicability Domains (AD) of Quantitative Structure-Activity Relationships (QSARs). AD models are conceived as meta-models designed to associate an untrustworthiness score to any molecule M subject to property prediction by a QSAR model. Untrustworthiness scores or "AD metrics" are an expression of the relationship between M (represented by its descriptors in chemical space) and the space zones populated by the training molecules at the basis of model μ. Scores integrating some of the classical AD criteria (similarity-based, box-based) were considered in addition to newly invented terms, such as the dissimilarity to outlier-free training sets and the correlation breakdown count.
A loose correlation is expected to exist between this untrustworthiness and the error affecting the predicted property. While high untrustworthiness does not preclude correct predictions, inaccurate predictions at low untrustworthiness must be imperatively avoided. This kind of relationship is characteristic for the Neighborhood Behavior (NB) problem: dissimilar molecule pairs may or may not display similar properties, but similar molecule pairs with different properties are explicitly "forbidden". Therefore, statistical tools developed to tackle this latter aspect were applied, and lead to a unified AD metric benchmarking scheme.
A first use of untrustworthiness scores resides in prioritization of predictions, without need to specify a hard AD border. Moreover, if a significant set of external compounds is available, the formalism allows optimal AD borderlines to be fitted. Eventually, consensus AD definitions were built by means of a nonparametric mixing scheme of two AD metrics of comparable quality, and shown to outperform their respective parents.
This article is published under license to BioMed Central Ltd.